First-line BRAF V600+
melanoma choice

What the case is

A melanoma oncologist choosing a first-line systemic regimen for unresectable/metastatic BRAF V600+ disease. Five approved options. Efficacy, safety, and treatment burden co-reside in one job.

Goal

Verify MEL-1L-E1 on raw coupled priority: nivo+ipi > nivo+rela. Mono-efficacy prefers nivo+ipi. Equal-weight prefers the gentler PD-1/LAG-3 pair.

How it was prepared

• Frozen public landmark-trial proxies for five 1L regimens.
• Three co-resident logics: efficacy, safety, treatment burden.
• Expectation locked before IBM submit. 18-qubit desk (5×3 + 3 junctions).

How it was computed

IBM Heron r2 · ibm_kingston · 4096 shots · job da1gvd6g52gs73clkp20. Transjunctions computed on the QPU. Primary readout: raw counts. Resilience is a labelled diagnostic channel on the same job.

How it was evaluated

PASS when the locked pair order holds on raw QPC priority. Full-panel ranks are reported. The industry finding is the pair.

Method	Order on the pair
Mono-efficacy	nivo+ipi > nivo+rela
Equal-weight	nivo+rela > nivo+ipi
QPC coupled raw	nivo+ipi > nivo+rela · PASS

Full melanoma report Atlas